Epigenetic drug discovery and tools
 

Management and Board

Management

 

    Barrie Ward   Executive Chairman
    Will West   Chief Executive
    Tim Fell  Chief Operating Officer
    David Knowles  Chief Scientific Officer
    Nessa Carey  Scientific Director
    Neil Pegg Director of Discovery Research
    Jonathan Best Programme Manager
    Dev Crease  Patent Counsel
    Richard Brooks Finance Director
    Thea Stanway  Finance Officer

  

Board

 

    Barrie Ward  Executive Chairman
    Will West  Executive Director
    Tim Fell Executive Director
    David Knowles Executive Director
    Gerald Chan Non-Executive Director
    Sue Foden Non-Executive Director
    Dan Roach Non-Executive Director
    David Secher Non-Executive Director
    Azim Surani Board Observer

 

Neil Pegg (Director of Discovery Research)

Neil PeggNeil was awarded a PhD in organic chemistry from the University of Nottingham in 1987, having completed undergraduate study at the University of Bristol. Following postdoctoral research at Ohio State University, Neil joined Glaxo in 1989, where he led successful teams working on both Lead Generation and Lead Optimization programmes. In 2001 Neil joined OSI Pharmaceuticals firstly as Associate Director of Oncology Chemistry and from 2003 as Director of UK Discovery Chemistry.

 

In 2005 Neil was appointed Research Director of ReOx Ltd, a start-up drug discovery company exploiting pioneering work in the field of hypoxia, before joining Piramed Ltd in 2006 as Director of Chemistry. Piramed was acquired by Roche in 2008. Neil has worked in several therapeutic areas, including Oncology, Immune/Inflammation, Pain, CNS and Cardiovascular Disease with direct involvement in multiple compounds progressing into Development.

 

Neil joined CellCentric in January 2009.